tradingkey.logo

Cumberland Pharmaceuticals Inc

CPIX
查看詳細走勢圖
4.410USD
+0.030+0.68%
收盤 12/19, 16:00美東報價延遲15分鐘
65.96M總市值
虧損本益比TTM

Cumberland Pharmaceuticals Inc

4.410
+0.030+0.68%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.68%

5天

+74.31%

1月

+122.17%

6月

+1.38%

今年開始到現在

+86.08%

1年

+94.27%

查看詳細走勢圖

操作建議

Cumberland Pharmaceuticals Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在藥品行業排名77/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價0.00。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Cumberland Pharmaceuticals Inc評分

相關信息

行業排名
77 / 158
全市場排名
192 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
持有
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Cumberland Pharmaceuticals Inc亮點

亮點風險
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
業績增長期
公司處於發展階段,最新年度總收入37.87M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入37.87M美元
估值低估
公司最新PE估值-19.06,處於3年歷史低位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉515.47K股

Cumberland Pharmaceuticals Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Cumberland Pharmaceuticals Inc簡介

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
公司代碼CPIX
公司Cumberland Pharmaceuticals Inc
CEOKazimi (A. J)
網址https://www.cumberlandpharma.com/

常見問題

Cumberland Pharmaceuticals Inc(CPIX)的當前股價是多少?

Cumberland Pharmaceuticals Inc(CPIX)的當前股價是 4.410。

Cumberland Pharmaceuticals Inc 的股票代碼是什麼?

Cumberland Pharmaceuticals Inc的股票代碼是CPIX。

Cumberland Pharmaceuticals Inc股票的52週最高點是多少?

Cumberland Pharmaceuticals Inc股票的52週最高點是7.250。

Cumberland Pharmaceuticals Inc股票的52週最低點是多少?

Cumberland Pharmaceuticals Inc股票的52週最低點是1.850。

Cumberland Pharmaceuticals Inc的市值是多少?

Cumberland Pharmaceuticals Inc的市值是65.96M。

Cumberland Pharmaceuticals Inc的淨利潤是多少?

Cumberland Pharmaceuticals Inc的淨利潤為-6.48M。

現在Cumberland Pharmaceuticals Inc(CPIX)的股票是買入、持有還是賣出?

根據分析師評級,Cumberland Pharmaceuticals Inc(CPIX)的總體評級為持有,目標價格為--。

Cumberland Pharmaceuticals Inc(CPIX)股票的每股收益(EPS TTM)是多少

Cumberland Pharmaceuticals Inc(CPIX)股票的每股收益(EPS TTM)是-0.231。
KeyAI